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Cherubism is an autosomal-dominant syndrome
characterized by inflammatory destructive bony
lesions resulting in symmetrical deformities of the
facial bones. Cherubism is caused by mutations in
Sh3bp2, the gene that encodes the adaptor protein
3BP2. Most identified mutations in 3BP2 lie within
the peptide sequence RSPPDG. A mouse model of
cherubism develops hyperactive bone-remodeling
osteoclasts and systemic inflammation character-
ized by expansion of the myelomonocytic lineage.
The mechanism by which cherubism mutations alter
3BP2 function has remained obscure. Here we show
that Tankyrase, a member of the poly(ADP-ribose)
polymerase (PARP) family, regulates 3BP2 stability
through ADP-ribosylation and subsequent ubiquity-
lation by the E3-ubiquitin ligase RNF146 in osteo-
clasts. Cherubism mutations uncouple 3BP2 from
Tankyrase-mediated protein destruction, which
results in its stabilization and subsequent hyperacti-
vation of the SRC, SYK, and VAV signaling pathways.
INTRODUCTION
Cherubism is a dominantly inherited disorder characterized by
facial disfigurement, early tooth loss, failure of permanent tooth
eruption, and distortion of the orbital socket creating an upturned
eye appearance occasionally associated with blindness (Jones
et al., 1950). Interosseous fibrocystic lesions arise in cherubism
patients as a result of highly activated osteoclasts and infiltrating
inflammatory and mesenchymal cells. The cherubism locus was
mapped to chromosome 4p16 (Tiziani et al., 1999) with subse-
quent identification of single missense mutations in the gene en-
coding the adaptor protein 3BP2 within this locus (Ueki et al.,1324 Cell 147, 1324–1339, December 9, 2011 ª2011 Elsevier Inc.2001). 3BP2 contains an N-terminal pleckstrin homology (PH)
domain, a proline-rich stretch that binds to Src homology (SH) 3
domain-containing proteins, and a C-terminal SH2 domain that
binds to phosphotyrosine residues (Deckert, 2006) (Figure 1D).
Most 3BP2 mutations associated with cherubism cluster within
peptide sequence RSPPDG lying between the PH and SH2
domains. A mouse model of cherubism in which the most
common disease-associated allele, P416R, was knocked into
the Sh3bp2 locus develops severe osteoporosis associated
with highly activated osteoclasts and demonstrated thatmutation
within this peptide sequence results in a gain-of-function pheno-
type (Ueki et al., 2007). Analysis of mice harboring two copies of
the cherubismallele uncovered 3BP2 as amajor governor ofmye-
lomonocytic homeostatic cell numbers. Homozygous mice die of
a systemic inflammation disorder at 25weeks of age as a result of
myelomonocytic infiltrationof theskin, synovial lining, andvisceral
organs associated with elevated serum TNF-a levels, trabecular
bone loss, and cortical bone erosions (Ueki et al., 2007).
3BP2 was originally identified as a binding protein of the tyro-
sine kinase ABL SH3 domain through proline-rich sequences
lying between the PH and SH2 domains (Cicchetti et al., 1992).
3BP2 is part of a multiprotein signaling complex composed of
the SRC family kinases (SFKs), SYK, and the RHO family guanine
nucleotide exchange factor VAV (Deckert and Rottapel, 2006)
and is required for optimal B cell antigen receptor (Chen et al.,
2007; de la Fuente et al., 2006) and integrin activation (Levaot
et al., 2011). The biochemical basis by which cherubism muta-
tions alter the activity of the 3BP2 adaptor protein has remained
elusive. The tight cluster of mutations in the peptide sequence of
3BP2 observed in cherubism patients suggested to us that this
sequence might define a protein interaction motif.
Here we identify the poly(ADP-ribose)polymerase (PARP)
family member Tankyrase as the protein that binds to the
RSPPDG sequence and serves to repress 3BP2 protein levels
through ADP-ribosylation and subsequent ubiquitylation by the
E3-ubiquitin ligase RNF146. We demonstrate that cherubism
mutations disrupt 3BP2 binding to Tankyrase and stabilize the
Figure 1. 3BP2 Cherubism Mutant Protein Is Stabilized
(A) 3BP2 protein expression in macrophages derived from WT, Sh3bp2KI/+, or Sh3bp2KI/KI mice was determined by western blot analysis.
(B) Quantitative PCR of sh3bp2 mRNA derived from WT, Sh3bp2KI/+, or Sh3bp2KI/KI macrophages. Error bars represent SEM.
(C) Cycloheximide chase to ascertain 3BP2 protein stability in WT or Sh3bp2KI/KI bone marrow-derivedmacrophages (BMMs). BMMs obtained from either WT or
Sh3bp2KI/KI mice were treated with cycloheximide for the indicated time intervals and lysed, and 3BP2 protein levels determined by western blot analysis. The
percentages of 3BP2 protein levels were plotted as a function of time.
(D) 3BP2 and TNKS2 domain organization. 3BP2 is a PH and SH2 domain-containing adaptor protein. The RSSPDG sequence mutated in cherubism patients is
shown. TNKS2 contains five repeat clusters (ARCs), a SAM domain, and the PARP domain.
(E) 3BP2 bind both TNKS and TNKS2. Myc-Tankyrase western blot of Flag-3BP2 immune complexes expressed in HEK293T cells.
(F) 3BP2 but not cherubism mutants bind to TNKS2. Tankyrase western blot of GST-3BP2 and GST-3BP2 cherubism mutant immune complexes.
(G) The 3BP2 targeting peptide (Hex) is sufficient to bind to TNKS2. Immobilized GST, GST-Hex(WT), or GST-Hex cherubismmutations R413Q, P416H, or G418R
were incubated with lysates from HEK293T cells overexpressing Myc-TNKS2 and probed for Myc-TNKS2 by western blot. The levels of the recombinant GST-
Hex peptide were evaluated by Coomassie staining.
See also Figure S1.
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Figure 2. 3BP2 Is ADP-Ribosylated by TNKS2 In Vitro and In Vivo
(A) Ribosylation of 3BP2 and TNKS2 in vitro require the SAM and PARP domains of TNKS2. Flag-3BP2 immune complexes were subjected to an in vitro PARP
reaction using [32P]NAD+. Proteins were separated by SDS-PAGE and visualized by autoradiography.
(B) The PARP inhibitor PJ-34 inhibits TNKS2-dependent ribosylation of 3BP2. Flag-3BP2 immune complexes were subjected to an in vitro PARP reaction in the
presence of increasing concentration of PJ-34. Lower panel, quantified inhibition of TNKS2 PARP activity by PJ-34, as evaluated by Myc-TNKS2 autor-
ibosylation.
(C) 3BP2 but not cherubismmutants of 3BP2 are ribosylated by TNKS2. Flag-3BP2 or Flag-3BP2 cherubismmutants were subjected to an in vitro PARP reaction.
Ribosylation was measured by autoradiography.
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3BP2 protein. Our accompanying manuscript (Guettler et al.,
2011 [this issue of Cell]) provides the structural basis of 3BP2
peptide recognition by the ankyrin repeats of Tankyrase, amech-
anism shared by all known Tankyrase substrates. The structural
insights enable us to rationalize how cherubism mutations allow
3BP2 to escape recruitment by Tankyrase. Elevated steady-state
protein levels of 3BP2 observed in primary osteoclasts derived
from cherubism mutant mice are associated with high levels of
SRC, SYK, and VAV activity, whereas osteoclasts lacking 3BP2
are unable to normally activate SRC, SYK, and VAV. Lastly, we
show that inhibition of Tankyrase in osteoclasts in vitro or deple-
tion of Tankyrase in vivo recapitulates many of the phenotypic
features of cherubism. These genetic and pharmacologic exper-
iments provide direct evidence that Tankyrase is a negative regu-
lator of the SRC signaling pathway through its action on 3BP2.
Our study elucidates the biochemical basis underlying the path-
ogenesis of cherubism and uncovers Tankyrase as a previously
unknown component of a regulatory pathway controlling bone
homeostasis and inflammatory cytokine production.
RESULTS
Cherubism Mutations Increase 3BP2 Protein Stability
We examined the levels of 3BP2 protein expressed in osteoclast
progenitors, primary bone marrow-derived macrophages from
wild-type (WT) mice (Figure 1A, lanes 1 and 2) or mice harboring
one (Sh3bp2KI/+) (Figure 1A, lanes 3 and 4) or two alleles
(Sh3bp2KI/KI) (Figure 1A, lanes 5 and 6) of the cherubismmutation
P416R. Strikingly, the steady-state level of 3BP2 was increased
in macrophages derived from both the hetero- and homozygote
cherubism mutant mice. Quantitative PCR indicated that the
levels of sh3bp2 mRNA in macrophages were similar between
the three different mice strains (Figure 1B). This observation
raised the possibility that cherubism arises as a result of a gain-
of-functionmutation leading to theaccumulationof 3BP2protein.
To determine whether the cherubism mutation altered the
stability of 3BP2, we performed a cycloheximide chase experi-
ment onWT- orSh3bp2KI/KI-derivedbonemarrowmacrophages.
As shown in Figure 1C, the half-life of the WT 3BP2 protein was
6.5 hr compared to 31.4 hr for the cherubism mutant form of
the protein. These data demonstrate that the P416R cherubism
mutation increases the protein stability of 3BP2.
3BP2 Binds to Tankyrase, an Interaction Disrupted
by Cherubism Mutations
We conjectured that the 3BP2-RSPPDG sequence might define
a docking site for a negative regulatory protein responsible for
controlling 3BP2 protein levels and that docking is impaired by
the cherubism mutations. We used the yeast two-hybrid system
with full-length 3BP2 as bait to identify 3BP2-binding proteins
from a hematopoietic cell library. From this screen we identified
Tankyrase 2 (TNKS2) as a potential 3BP2-interacting protein.
TNKS2 is a member of the PARP family of proteins, which cata-(D)RibosylatedTNKS2 ispresent in3BP2butnotcherubismmutantprotein comple
protein complexeswere dissociated in 1%SDSheated to 68C then subjected to r
(E) Endogenous 3BP2 but not a cherubism mutant is ribosylated in primary o
Sh3bp2KI/KI bone marrow-derived osteoclasts were probed with anti-PAR-specilyze the addition of ADP-ribose from NAD+ to acceptor proteins.
TNKS2 is most closely related to Tankyrase 1 (TNKS), a protein
originally identified as a repressor of the telomerase inhibitor
TRF1/TERF1 (Smith et al., 1998). TNKS and TNKS2 contain five
ankyrin repeat clusters (ARCs, see accompanying manuscript
[Guettler et al., 2011]), a sterile-alpha motif (SAM) domain medi-
atingmultimerization, and thePARPcatalytic domain (Figure 1D).
We showed that epitope-tagged versions of both TNKS and
TNKS2 bind to 3BP2 in transfected HEK293T cells (Figure 1E).
We next tested the capacity of 3BP2 proteins harboring any
one of three independent cherubism mutations within the
RSPPDG motif, R413Q, P416H, or G418R, to bind to TNKS2
and showed that none of the cherubism mutants were able to
bind to TNKS2 (Figure 1F, lane 5–7). In contrast, a mutant form
of 3BP2 that contains a mutation in its SH2 domain (R486K),
rendering it unable to bind to phosphotyrosine-containing
proteins (Sada et al., 2002), bound to TNKS2 comparably to the
WT protein (Figure 1F, lane 4). These data demonstrate that the
cherubismmutations disrupt binding between 3BP2 and TNKS2.
A recombinant GST-fusion protein containing the 3BP2
RSPPDG six amino acid sequence (GST-Hex) immobilized on
glutathione Sepharose was sufficient to recruit TNKS2 from
HEK293T cell lysates (Figure 1G, lane 5) but not resin alone or
resin coupled to GST (Figure 1G, lanes 3 and 4). However,
GST-Hex peptides containing any of the three cherubism muta-
tions failed to interact with TNKS2 (Figure 1G, lanes 6–8). These
data and those presented in Figure 1F show that the RSPPDG
sequence in 3BP2 mutated in cherubism patients is both neces-
sary and sufficient to mediate binding with TNKS2.
Wemapped the interaction between 3BP2andTNKS2by dele-
tionmutagenesis. TNKS2 constructs lacking either the first or the
secondhalf of theankyrin regionbound to 3BP2,whereasbinding
was lost when the entire ankyrin region was deleted (Figure S1
available online). This suggests that 3BP2 likely binds to more
thanoneof theARCs inTNKS2asconfirmed inouraccompanying
manuscript (Guettler et al., 2011). The interaction between 3BP2
and TNKS2 was not dependent on the SAM domain (Figure S1).
Using fluorescence polarization, we quantified binding between
the recombinant N-terminal region of TNKS2 containing all five
ARCsand the 3BP2Tankyrase-targetingpeptide anddetermined
a dissociation constant of 0.5 ± 0.1 mM (see Guettler et al., 2011).
Wild-Type 3BP2 but Not 3BP2 Cherubism Mutants
Are Ribosylated by Tankyrase
To determine whether 3BP2 is a TNKS2 substrate, we performed
an in vitro ribosylation assay. Radioactive [32P]NAD+ was added
as a source of ADP-ribose to 3BP2 immune complexes precipi-
tated fromHEK293T cells overexpressing TNKS2 and 3BP2. The
reaction was resolved by SDS-PAGE and revealed by autoradi-
ography. We observed two bands corresponding to the size of
3BP2 (80 kDa) and TNKS2 (120 kDa), respectively, or a yet
to be identified copurifying protein (Figure 2A, lane 2).
Ribosylation wasmuch stronger for the higher-molecular-weightxes. Flag-3BP2andMyc-TNKS2werecoexpressed inHEK293Tcells. Flag-3BP2
eprecipitationwith an anti-Myc antibody and probedwith an anti- PAR antibody.
steoclasts. Western blots of 3BP2 immune complexes derived from WT or
fic antibodies. See also Figure S2.
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Figure 3. TNKS2 Controls 3BP2 Protein Levels through Ubiquitin-Mediated Proteolysis
(A) Proteasome inhibition by MG132 and LLnL reverses TNKS2-dependent suppression of 3BP2 protein levels.
(B) Ubiquitylation of 3BP2 is stimulated by TNKS2 and requires PARP activity. HEK293T cells were transfected with TNKS2 and HA-ubiquitin and incubated with
proteosome or PARP inhibitors as indicated. Endogenous 3BP2 was immunoprecipitated and probed for HA-ubiquitin.
(C) TNKS2 stimulates ubiquitin-K48 modification of 3BP2. GST-3BP2 or GST-3BP2R413Q was expressed in HEK293T in the absence or presence of TNKS2.
GST-3BP2 proteins were precipitated and probed with anti-UbK48-specific antibodies.
(D) The E3-ubiquitin ligase RNF146 binds to 3BP2 but not a cherubism mutant. Flag-3BP2 or Flag-3BP2R413Q immune complexes were probed for HA-RNF146
or Myc-TNKS2. The levels of protein expression for each condition are indicated in the panels below.
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species compared to the lower-molecular-weight protein and
was dependent on an intact TNKS2 SAMand PARP domain (Fig-
ure 2A, lanes 3 and 4). Addition of the PARP inhibitor PJ-34
(10 mM) at a concentration above the half-maximal inhibitory
concentration (IC50) for Tankyrasewas sufficient to inhibit ribosy-
lation of both the lower- and higher-molecular-weight ribosy-
lated species (Figure 2B, lane 3).
To determine the effect of the cherubism mutation on 3BP2 ri-
bosylation, we subjected three mutant forms of 3BP2, R413Q,
P416H, or G418R, derived from cherubism patients to an
in vitro ribosylation assay. Whereas WT 3BP2 and TNKS2
formed a complex and were ribosylated (Figure 2C, lane 3),
none of the three cherubism mutants bound to TNKS2 nor
became ribosylated (Figure 2C, lanes 4–6), suggesting that the
biochemical defect observed in cherubism may result from the
failure of 3BP2 to bind to TNKS2 and be modified by ADP-ribose
conjugation.
To confirm the identity of the ribosylated 120 kDa species
present in 3BP2 immune complexes, we dissociated proteins
in 1%heated SDS, reprecipitated TNKS2, and probed the immu-
noprecipitates with either an antibody that recognizes ADP-
ribose (PAR) or an anti-TNKS2 antibody. We confirmed that
TNKS2 is autoribosylated in 3BP2 immune complexes (Fig-
ure 2D, lane 3) but not in cherubism mutant 3BP2 protein
complexes (Figure 2D, lanes 4–6).
We next sought to determine whether endogenous 3BP2 is
ribosylated in primary osteoclasts. 3BP2 immune complexes
derived from WT or Sh3bp2KI/KI osteoclasts were probed with
the anti-PAR antibody. We observed that endogenous 3BP2
was ribosylated and was associated with an abundantly ribosy-
lated protein with a molecular weight similar to TNKS2 and high-
molecular-weight ribosylated species of unknown identity. Ribo-
sylation was dramatically reduced in 3BP2 protein complexes
derived from osteoclasts obtained from cherubism mice (Fig-
ure 2E). Again we noticed that the level of 3BP2 protein present
in the Sh3bp2KI/KI-derived osteoclasts was significantly elevated
compared to theWT controls (Figure 2E, row 2). We showed that
an N-terminal fragment of 3BP2 containing the RSPPDG
sequence and a C-terminal fragment beginning with the
RSPPDG sequence were both ribosylated by Tankyrase,
showing that 3BP2 is either modified at multiple sites throughout
the protein, or a single ribosylation site lies in the 13 amino acid
stretch common to both constructs (Figure S2A).
Although we found that the Tankyrase-binding sequence in
3BP2 is sufficient for the recruitment of Tankyrase (see above),
it remained possible that its position in 3BP2 contributes to
Tankyrase recruitment and/or ribosylation. To determine the
positional effects of the Tankyrase-binding sequence on 3BP2
stability and ribosylation, we created a chimeric protein in which(E) Binding of RNF146 to 3BP2 is ADP-ribosylation dependent. Flag-3BP2 or Flag
Tankyrase inhibitor XAV-939 were probed for HA-RNF146 or Myc-TNKS2.
(F) Ubiquitylation of 3BP2 requires the ring finger and the WWE domain of RNF14
3BP2 ubiquitylation. HA-RNF146, HA-RNF146DWWE, or HA-RNF146DRF were c
were probed with anti-UbK48-specific antibodies.
(G) Depletion of RNF146 stabilizes 3BP2 protein levels. HEK293T cells were transf
nonspecific shRNAs. Endogenous 3BP2 and actin proteins were probed by wes
See also Figure S3.the nonmutated RSPPDG sequence was added to the C
terminus of the cherubism mutant 3BP2R413Q. Tankyrase was
able to bind to the chimeric protein but was unable to alter the
steady-state levels of the chimeric protein or induce ribosylation
(Figures S2B–S2D). These data suggest that 3BP2 ribosylation
and destabilization are sensitive to the position of the Tankyr-
ase-binding sequence in 3BP2.
Ribosylation of the Wild-Type but Not a Cherubism
Mutant Form of 3BP2 by TNKS2 Induces 3BP2
Ubiquitylation and Subsequent Degradation
We investigated whether TNKS2 could directly regulate 3BP2
protein levels. Wild-type 3BP2 or the cherubism mutant
3BP2R413Q was coexpressed with increasing amounts of the
TNKS2 expression vector. We observed that whereas the
steady-state level of 3BP2 was inversely related to TNKS2
protein level, the 3BP2R413Qmutant was resistant to the effects
of TNKS2 overexpression (Figure S3A). To determine whether
the PARP domain was required for TNKS2-induced 3BP2 desta-
bilization, we repeated the experiment with a PARP domain-
deleted mutant form of TNKS2. Although TNKS2DPARP and
3BP2 formed a complex (see Figure S3B, row 3), 3BP2 protein
levels were unaffected by increasing levels of TNKS2DPARP
(Figure S3B). These data show that the ability of TNKS2 to per-
turb 3BP2 protein levels is not a result of binding alone but
requires the intact TNKS2 catalytic domain.
We sought to elucidate the mechanism underlying the regula-
tion of 3BP2 protein stability by TNKS2. Conceivably, TNKS2-
mediated ribosylation could mark 3BP2 for ubiquitylation and
subsequent proteasome-mediated degradation. To test this
possibility, we coexpressed 3BP2 and TNKS2 in the absence
or presence of proteasome inhibitors. We observed that the
diminished steady-state levels of 3BP2 resulting from coexpres-
sion of TNKS2 were reversed in the presence of proteasome
inhibitors (Figure 3A). We noticed that TNKS2 levels were dimin-
ished when coexpressed with WT 3BP2 but not cherubism
mutants (Figures 1E, 1F, 2C, and 2D), suggesting that both
components of the complex are rendered unstable by the inter-
action and stabilized by proteasome inhibition. We sought to
determine whether endogenous 3BP2 was ubiquitylated in
response to TNKS2 expression. A tagged version of ubiquitin
was expressed in cells in the presence or absence of ectopically
expressed TNKS2. Endogenous 3BP2 was then immunoprecip-
itated and probed by western blotting for ubiquitin modification.
Whereas little ubiquitin was detected in 3BP2 immunoprecipi-
tates in the absence of TNKS2, intense ubiquitylation of proteins
present in the 3BP2 complex, seen as a diffuse smear, was
induced when TNKS2 was coexpressed (Figure 3B, lane 2
versus lane 4).-3BP2R413Q immune complexes derived from cells cultured in the presence of
6. HA-RNF146 but not HA-RNF146DWWE or HA-RNF146DRF mutants induce
oexpressed with Flag-3BP2 and Myc-TNKS2. Flag-3BP2 immune complexes
ected with one of three individual shRNAs targeting RNF146 (shRNF1–3) or two
tern blot.
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Figure 4. Elevated Levels of Wild-Type 3BP2 Protein Are Sufficient to Induce Enhanced Osteoclast Formation and TNF-a Secretion by
Macrophages
(A) Lysates from RAW264.7 cell infected with retroviruses expressing WT Flag-3BP2, Flag-3BP2P416R, or empty vector were probed with anti-Flag antibodies.
(B) TRAP-positive multinucleated osteoclast cells derived from RAW264.7 infected cells as in (A). Images obtained using a Leica inverted microscope with 53
objectives.
(C) TNF-a levels in supernatants from RAW264.7 infected cells as in (A) from four independent experiments are shown. Error bars represent SEM.
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To determine whether TNKS2 PARP activity was required to
stimulate 3BP2 ubiquitylation, we repeated the experiment in
the presence of the nonselective PARP inhibitor PJ-34 and
observed that the TNKS2 induction of 3BP2 ubiquitylation was
blocked (Figure 3B, lanes 5 and 6). We confirmed that 3BP2 is
itself ubiquitylated, by a precipitation-reprecipitation experiment
under denaturing conditions (Figure S3C). These data show that
endogenous 3BP2 ubiquitylation is stimulated by TNKS2 and
requires PARP activity.
To ascertain the form of TNKS2-dependent ubiquitinmodifica-
tion of 3BP2, we used a monoclonal antibody, which recognizes
lysine 48 (Ub-K48), and observed that TNKS2 induced intense
stepwise K48 ubiquitin modification, likely of 3BP2 (Figure 3C,
lane 2). To determine the effect of the cherubism mutation on
3BP2 ubiquitylation, we expressed WT 3BP2 or the cherubism
mutant 3BP2R413Q in the absence or presence of TNKS2.
Whereas WT 3BP2 became polyubiquitylated in the presence
of TNKS2, the 3BP2 cherubism mutant poorly incorporated
ubiquitin (Figure 3C, lanes 3 and 4).
The E3-ubiquitin ligase RNF146 has recently been shown to
regulate the Tankyrase-dependent ubiquitylation of Axin2
(Zhang et al., 2011). RNF146 may be widely employed as an
ubiquitin ligase for additional Tankyrase substrates, and we
tested whether RNF146 also targets ribosylated 3BP2. We
showed that RNF146 binds to 3BP2 but not to a cherubism
mutant or to WT 3BP2 in cells in which Tankyrase PARP activity
has been inhibited by the Tankyrase-selective inhibitor XAV939
(Figures 3D and 3E). Importantly, coexpression of RNF146 abol-
ished the detection of the 3BP2:Tankyrase complex, suggesting
that RNF146 might be part of a destruction complex involving
3BP2 and Tankyrase (Figures 3D and 2E, 2nd row). Moreover,
WT RNF146, but not a mutant form of the ligase lacking its ring
finger or the WWE ADP-ribose-binding domain, potently stimu-
lated K48 ubiquitylation of 3BP2 (Figure 3F). Depletion of
RNF146 in HEK293T cells by three independent interfering
RNA hairpin lentiviruses, which efficiently knocked down
RNF146 transcript, resulted in increased steady-state levels of
3BP2 (Figures 3G and S3D), demonstrating that RNF146 is the
functional E3-ligase controlling 3BP2 protein levels.
Elevated Levels of Wild-Type 3BP2 Protein
Are Sufficient to Induce Enhanced Osteoclast
Formation and TNF-a Secretion by Macrophages
Our data demonstrate that cherubism mutations result in the
stabilization of 3BP2 protein as a result of loss of repression by
Tankyrase. We next asked whether the cherubism-associated
characteristics of an in vitro culture of osteoclasts result from
elevated 3BP2 levels or from some other neomorphic changes(D) SRC, SYK, and VAV are hyperphosphorylated in Sh3bp2KI/KI osteoclasts. Lys
phosphospecific antibodies against SRC, SYK, or VAV (left panel). The total prot
(E) SRC kinase activity is elevated in Sh3bp2KI/KI osteoclasts. Bone marrow-deri
subjected to a SRC-specific immune complex in vitro kinase reaction. The specific
the level of SRC expression.
(F) SYK immune complex in vitro kinase reaction performed as in (E).
(G) RAC-GTP levels are elevated inSh3bp2KI/KI osteoclasts. RAC-GTP levels in ost
pull-down assay. RAC-GTP levels in the WT osteoclasts were normalized to 1,
compared to WT values.associated with these mutations. We overexpressed WT 3BP2
or the cherubism mutant allele P416R at similar levels using
retroviral transduction in the RAW264.7 monocytic cell line,
which have osteoclastogenic potential (Figure 4A). We observed
that overexpression of either WT 3BP2 or the 3BP2P416R cher-
ubism mutant induced the formation of multinucleated Tartrate-
resistant acid phosphatase (TRAP) positive cells in the absence
of RANKL while no multinucleated cells were observed in empty
vector-transduced control cells (Figure 4B). Moreover,
RAW264.7 cells ectopically expressing either WT or a cherubism
mutant variant of 3BP2 secreted high levels of TNF-a compared
to vector-infected controls (Figure 4C). These results demon-
strate that elevated levels of WT 3BP2 protein are sufficient to
induce enhanced osteoclast formation in the absence of RANKL
and increased TNF-a secretion by macrophages consistent with
the idea that the basis of cherubsim results from elevated levels
of 3BP2 and not due to a neomorphic protein property of the
protein.
Enhanced Activation of SRC, SYK, and VAV
in Cherubism Osteoclasts
3BP2 nucleates a signaling complex that contains SRC kinases,
SYK, and the guanine nucleotide exchange factor VAV (Deckert
and Rottapel, 2006). To understand the effect of 3BP2 stabiliza-
tion on the signaling pathways that 3BP2 connects to, we
examined the phosphorylation levels of SRC, SYK, and VAV as
a surrogate of their activation state. SRC, SYK, and VAV were
highly tyrosine phosphorylated in osteoclasts derived from
Sh3bp2KI/KI mice compared to osteoclasts from control mice,
whereas total SYK, SRC, and VAV protein levels were similar in
osteoclasts derived from both mouse strains (Figure 4D). To
verify that the activities of SRC and SYK were elevated, we per-
formed in vitro kinase assays on both proteins. Both SRC (Fig-
ure 4E) and SYK (Figure 4F) autophosphorylation levels were
elevated in cherubism osteoclasts compared to normal controls.
Similarly, the increased levels of VAV phosphorylation correlated
with elevated levels of RAC-GTP in the osteoclasts from cherub-
ism mice as measured by a PAK-CRIB RAC binding pull-down
assay (Figure 4G, lanes 3 and 6).
TNKS/TNKS2-Depleted Osteoclasts Phenocopy
Cherubism Osteoclasts
To test whether the failure of TNKS2-mediated negative regula-
tion of 3BP2 observed in cherubism osteoclasts accounted for
their activated phenotype, we examined whether TNKS2-defi-
cient osteoclasts phenocopied cherubism osteoclasts. Wild-
type macrophages normally complete osteoclastogenesis
in vitro within 5 to 6 days when cultured in RANKL and CSF-1.ates from osteoclasts derived from WT or Sh3bp2KI/KI mice were probed with
ein levels are shown respectively on the right panel.
ved osteoclasts from either WT (lane 1) or Sh3bp2KI/KI (lane 2) were lysed and
kinase activity was calculated as the ratio of the autophosphorylation signal to
eoclast-derivedWT orSh3bp2KI/KImiceweremeasured using a PAKGST-PBD
and RAC-GTP levels in Sh3bp2KI/KI osteoclasts expressed as fold difference
Cell 147, 1324–1339, December 9, 2011 ª2011 Elsevier Inc. 1331
Figure 5. Primary Bone Marrow-Derived Macrophages Depleted of TNKS/TNKS2 Undergo Accelerated Osteoclastogenesis
(A) TNKS/TNKS2-deficient osteoclasts phenocopy cherubism osteoclasts. BMMs fromWT, Sh3bp2KI/KI, or Tnks2/mice were infected with scrambled shRNA
retrovirus (first three rows). BMMs derived from Tnks2/ mice were infected with tnks-specific shRNA retrovirus (fourth row). Cells were then grown in CSF-1
(30 ng/ml) and RANKL (5 ng/ml, 10 ng/ml, or 40 ng/ml) for 3 days to initiate osteoclastogenesis, then TRAP stained. Experiments were performed in triplicate.
Scale bar: 50 mm.
(B) Both tnks and tnks2mRNA are expressed in osteoclasts. TankyrasemRNA levels in BMMs cultured in RANKL and CSF-1 as determined by qPCR at day 0 and
day 5. *p < 0.05; NS, no statistical significance. Error bars represent SEM.
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We cultured bone marrow monocytes (BMMs) from WT or
Tnks2/ mice in the presence of increasing doses of RANKL
for the suboptimal period of 3 days and observed an enhanced
rate of in vitro osteoclastogenesis intermediate between WT
and Sh3bp2KI/KI macrophages (Figure 5A, rows 1–3). Because
TNKS and TNKS2 have overlapping essential function during
embryonic development (Chiang et al., 2008), we conjectured
that TNKS may also participate in 3BP2 negative regulation in
osteoclasts. We observed that both tnks and tnks2 mRNAs are
expressed during osteoclast differentiation (Figure 5B) and
demonstrated that TNKS can bind to and PARsylate 3BP2
when coexpressed in HEK293T cells (Figures 1E and S4A). We
therefore depleted tnks mRNA in the Tnks2/ BMMs using
a lentivirus shRNA specific for tnks (Figure 5C) and observed
that BMMs lacking both TNKS and TNKS2 underwent acceler-
ated osteoclastogenesis closely resembling the activated osteo-
clast phenotype observed in cherubism osteoclasts (Figure 5A,
row 4). Moreover, we noted that in TNKS/TNKS2-depleted cells,
SRC, SYK, and VAVwere highly phosphorylated and 3BP2 levels
were elevated (Figures 5D, lane 4 and 5E, lane 4, row 4). These
results were observed with a second tnks-depleting hairpin lenti-
virus (data not shown). These data demonstrate that both Tank-
yrase family proteins participate in the repression of 3BP2
protein levels and the control of SRC, SYK, and VAV activation
in macrophages and osteoclasts. Lastly, we observed that WT
macrophages depleted of RNF146 similarly underwent acceler-
ated osteoclastogenesis with elevated 3BP2 levels reminiscent
of the Sh3bp2KI/KI or Tankyrase-depleted macrophages (Figures
5F, 5G, and S4B). This effect was dependent on 3BP2 as
RNF146 depletion in 3BP2 knockout cells had little effect on
in vitro osteoclastogenesis. RNF146 therefore controls osteo-
clast activity by regulating 3BP2 levels in an ADP-ribose-depen-
dent manner.
Tankyrase Inhibition Promotes Osteoclastogenesis
and TNF-a Secretion by Macrophages
To determine whether the activated osteoclast phenotype
observed in cells depleted of TNKS/TNKS2 was dependent on
3BP2, we applied the nonselective PARP inhibitor PJ-34 or the
recently described TNKS/TNKS2-specific inhibitor IWR-1
(Chen et al., 2009; Huang et al., 2009) to either WT or 3BP2-
deficient BMMs cultured under osteoclastogenic conditions.
Exposure of WT BMMs to either PJ-34 or IWR-1 resulted in
acceleration of osteoclast formation compared to untreated
control cells (Figure 6A, top row). 3BP2-deficient BMMs,
however, were completely resistant to the pro-osteoclast effects
of either inhibitor (Figure 6A, bottom row), demonstrating that(C) tnks mRNA levels in Tnks2/ osteoclasts infected with scrambled or tnks-sp
(D and E) TNKS/TNKS2-depleted osteoclasts express elevated levels of phospho
primary osteoclasts in (A) were probed with phosphospecific antibodies against S
shown (E).
(F) RNF146-deficient osteoclasts phenocopy cherubism osteoclasts. BMMs from
shRNA were grown in CSF-1 (30 ng/ml) and RANKL (5 ng/ml) for 3 days the
comparison. Experiments were performed in triplicate. Scale bars: 50 mm.
(G) RNF146-depleted osteoclasts express elevated levels of 3BP2. Lysates fr
(shrnf146-1 and shrnf146-2) or a scrambled shRNA (shscm) were probed by wes
See also Figure S4.3BP2 is the relevant Tankyrase target in these inhibition studies.
Osteoclasts treated with either PJ-34 or IWR-1 exhibited
increased levels of phosphorylated SRC, SYK, and VAV and
elevated levels of 3BP2 protein compared to control cells
(Figures 6B, lanes 1–3 and 6C, row 4, lanes 1–3). Moreover,
SRC, SYK, and VAV failed to become phosphorylated in cells
lacking 3BP2 treated with PARP inhibitors (Figure 6B, lanes
4–6), demonstrating that 3BP2 is an obligate factor required for
SRC pathway activation in osteoclast differentiation. We next
tested the effect of Tankyrase inhibition on basal TNF-a produc-
tion in macrophages. We observed that WT macrophages
treated with CSF-1 and IWR-1 for 36 hr secreted 2-fold higher
levels of TNF-a compared with vehicle controls (Figure 6D) and
at levels similar to Sh3bp2KI/KI-derived macrophages, whereas
there was no induction of TNF-a observed in treated
Sh3bp2/-derived macrophages. These data provide conclu-
sive evidence that TNKS/TNKS2 negatively regulate the activa-
tion of SRC and its downstream targets SYK and VAV in osteo-
clasts by controlling the abundance of 3BP2. Moreover,
genetic depletion or pharmacologic inhibition of Tankyase re-
sulted in an increased response of myeloid cells to CSF-1, an
effect phenocopied by the Sh3bp2KI/KI-derived monocytes.
To test whether SRC activity is required for Tankyrase- and
3BP2-mediated osteoclast differentiation, we applied the SRC
inhibitors AZD0530 or PP1 to WT or Sh3bp2KI/KI-derived
macrophages under osteoclastogenic conditions. Incubation
with either inhibitor blocked osteoclast formation of both WT
and Sh3bp2KI/KI-derived BMMs (Figure 6E). Moreover, addition
of these SRC inhibitors to WT BMM cultures treated with the
PARP inhibitor IWR-1 similarly blocked osteoclast formation
(Figure 6F). Taken together, the results demonstrate that
SRC is required as a downstream effector of the Tankyrase-
3BP2 signaling module and that hyperactivation of osteoclasts
mediated by stabilized 3BP2 can be antagonized by SRC
inhibition.
Radiation Chimeric Mice that Lack TNKS/TNKS2
Copy the Phenotype of Sh3bp2KI/KI Mice
Our observations suggest that Tankyrase proteins may have
a physiologic role in regulating bone homeostasis, in myelomo-
nocytic expansion, and in controlling inflammatory cytokines
as observed in the Sh3bp2KI/KI mice. We predicted that mice
lacking Tankyrases within the bone marrow compartment would
recapitulate these features of the cherubism mice. We analyzed
the trabecular bone volume and serum TNF-a levels of 22-week-
old Tnks2/mice and observed no difference in these parame-
ters compared to age-matched WT littermate controlsecific shRNA retrovirus as determined by qPCR. Error bars represent SEM.
rylated SRC, SYK, and VAV and increased levels of 3BP2 protein. Lysates from
RC, SYK, or VAV (D). The total protein levels as determined by western blot are
WT or Sh3bp2/ mice infected with scrambled shRNA or RNF146-specific
n TRAP stained. Cultured osteoclasts from Sh3bp2KI/KI mice are shown for
om primary osteoclasts expressing two different RNF146-targeting shRNAs
tern blot for 3BP2 protein expression.
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Figure 6. Tankyrase Inhibition Enhances Osteoclastogenesis in a 3BP2-Dependent Manner
(A) BMMs harvested fromWT or Sh3bp2/mice were grown under osteoclastogenic conditions in the presence of IWR-1 (2 mM) or PJ34 (2 mM) and then TRAP
stained. Scale bars: 50 mm.
(B and C) Osteoclasts grown in the presence of IWR-1 or PJ-34 express elevated levels of activated SRC, SYK, and VAV and increased protein levels of 3BP2.
Lysates from cells treated as in (A) were blottedwith phosphospecific antibodies against SRC, SYK, or VAV, as in Figure 5D. (C) SRC, SYK, VAV, and 3BP2 protein
levels as determined by western blot are shown.
(D) TNF-a levels in the supernatant of primary macrophages incubated for the indicated times with CSF-1 in the presence or absence of IWR-1 (2 mM). Error bars
represent SEM.
(E) BMMs harvested fromWT and Sh3bp2KI/KI mice were cultured under osteoclastogenic conditions in the presence of the SRC inhibitors AZD0530 (0.5 mM) or
PP1 (5 mM) then TRAP stained. Scale bars: 50 mm.
(F) WT BMMs were cultured under osteoclastogenic condition in the presence of IWR-1 and either AZD0530 (0.5 mM) or PP1 (5 mM) then TRAP-stained. Scale
bars: 50 mm.
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(Figures S5A–S5C). The failure of Tnks2/mice to show a cher-
ubism-like phenotype could be the result of the redundant func-
tion of TNKS in the hematopoietic compartment. To test whether
loss of both TNKS and TNKS2 in the hematopoietc system could
recapitulate the cherubism phenotype, we created chimeric
mice in which TNKS was knocked down in the Tnks2/ back-
ground. We depleted TNKS by RNAi-mediated knockdown
with a lentivirus harboring a Tnks-specific shRNA in lineage-
depleted Tnks2/ bone marrow cells (C57Bl/6, CD45.2). In-
fected bone marrow cells were then injected into lethally
irradiated, syngeneic (CD45.1) recipient mice. Wild-type trans-
plantation control chimeric mice were generated from CD45.2-
derived bone marrow cells infected with a lentivirus expressing
a scrambled shRNA hairpin (Figure 7A). Fifteen weeks after
transplantation, we evaluated engraftment by measuring the
percentage of CD45.2-positive leukocytes in the peripheral
blood. Both WT control and TNKS/TNKS2-depleted bone
marrow engrafted at similar levels of 38% of peripheral blood
leukocytes (Figure 7B). TNKS/TNKS2-deficient chimeras
showed a trend toward expansion of the CD11b-positive myelo-
monocytic cells compared to WT chimeras (30% versus 14% of
blood leukocytes, respectively; p = 0.16) (Figure 7C), suggesting
that TNKS/TNKS2 are required to restrain expansion of the
myelomonocytic lineage. We then analyzed the trabecular
bone volume/total bone volume ratio (BV/TV) of the chimeric
mice from each group by microcomputer tomography (mCT).
Relative to the WT chimeric mice, we observed that the TNKS/
TNKS2 chimeric mice had a dramatic reduction in trabecular
bone volume of 33% (Figure 7D). TRAP staining of tibias of
TNKS/TNKS2-deficient chimeras showed a profound increase
in TRAP-positive cells compared to WT chimeras (red stain, Fig-
ure 7E). Histomorphometric analysis showed a 2-fold increase in
the ratio of osteoclast surface to total bone surface and a 70%
increase in osteoclast number per bone surface in TNKS/
TNKS2-deficient chimeras (Figures 7F and 7G). We next exam-
ined the in vitro culture properties of osteoclasts from both
sets of chimeric mice and observed enhanced osteoclastogene-
sis of BMMs derived from TNKS/TNKS2 chimeric mice, charac-
teristic of the cherubism phenotype (Figure 7H). These data
provide strong genetic evidence that ablation of TNKS/TNKS2
in vivo phenocopies the hallmark features of bone loss and acti-
vated osteoclasts characteristic of cherubism.
DISCUSSION
In this study, we uncover an enzyme-substrate relationship
between the PARP Tankyrase and 3BP2, a signaling adaptor
protein upstream of SRC kinases, which is mutated in cherub-
ism. Tankyrase-mediated poly(ADP-ribosyl)ation promotes
3BP2 turnover by targeting it to the ubiquitin-proteasome
machinery. We show that mutations that give rise to cherubism
stabilize 3BP2 and thereby increase its signaling potential to
drive osteoclast differentiation characteristic of the cellular
dysfunction underlying cherubism. We examined whether cher-
ubism mutations might confer neomorphic properties to 3BP2
that are responsible for the cherubism phenotype. We observed
that overexpression of the WT 3BP2 protein was sufficient to
induce osteoclast formation (even in the absence of RANKL)and elevated TNF-a secretion in macrophages, two critical
featuresof thecherubismphenotype. Thesedataargue that stabi-
lization of 3BP2protein is the basis for the hypermorphic behavior
of cherubism variants of 3BP2 and provide an explanation for the
autosomal-dominant inheritance of the disease. The ability of
overexpressed 3BP2 to manifest cherubism-like effects is there-
fore not likely to be due to a neomorphic property of the protein
resulting from these mutations but rather is due to the intrinsic
accentuated property of the WT 3BP2 protein. Cherubism muta-
tions reside within a Tankyrase-recruiting peptide motif in 3BP2
and abolish recognition of 3BP2 by Tankyrase. In an accompa-
nyingmanuscript (Guettler et al., 2011),weprovideacrystal struc-
ture of the 3BP2 peptide bound to a TNKS2 ankyrin repeat and
determine the general rules for substrate recognition by Tankyr-
ase. It is important to note that all of the known cherubism muta-
tions described to date (Lietman et al., 2006) violate these rules,
providing further evidence for the role of disrupted Tankyrase
binding as the cause of cherubism. We have highlighted the
importance of this interaction by showing that interference with
Tankyrase expression or activity in vitro similarly leads to
enhanced 3BP2 expression and to hyperactivated osteoclasts
and increased TNF-a production by monocytes. Lastly, we have
shown that the characteristic cherubism features of bone loss,
increasednumbersof in situTRAP-positiveosteoclasts, andmye-
lomonocytic expansion can be recapitulated in vivo in TNKS/
TNKS2-deficient bone marrow chimeric mice.
These studies have highlighted that 3BP2 is a concentration-
limited factor required for SRC activation in osteoclasts and
that modulation of the steady-state levels of 3BP2 tightly
controls SRC activity and downstream signaling proteins in
these cells. We demonstrated that SRC inhibition blocked osteo-
clastogenesis associated with cherubism or Tankyrase-inhibited
BMMs, suggesting that SRC lies downstream of 3BP2 or is
a generally required component for osteoclast formation. These
studies also suggest that therapeutic use of SRC kinase inhibi-
tors might benefit cherubism patients.
The biologic function of the Tankyrase proteins is complicated
by the multiplicity of identified binding proteins. Mice lacking
TNKS or TNKS2 develop normally through embryogenesis.
However, adult Tnks/ mice suffer from a metabolic disorder
(Yeh et al., 2009), whereas Tnks2/ mice have a short stature
phenotype (Chiang et al., 2006; Hsiao et al., 2006). Mice lacking
both TNKS and TNKS2 die in utero at post-coital day 10, demon-
strating that Tankyrase proteins have an essential but redundant
function during embryonic development (Chiang et al., 2008).
TNKS was originally identified as a negative regulator of the telo-
merase inhibitor TRF1/TERF1 (Smith et al., 1998). TRF1/TERF1
is similarly regulated by ADP-ribosylation and ubiquitin-medi-
ated proteolysis (Chang et al., 2003). More recently, Tankyrases
have been identified as positive regulators of the Wnt/b-catenin
pathway through their capacity to negatively regulate AXIN
through ADP-ribosylation and ubiquitylation (Huang et al.,
2009). Both TNKS and TNKS2 bind to the mitotic spindle regu-
lator NUMA, but TNKS alone is required for NUMA ribosylation
and proper mitotic spindle organization (Chang et al., 2005).
TNKS and TNKS2 bind to a common set of proteins, including
insulin-responsive amino peptidase (IRAP), TAB182, and
FBP17, all of whom share a common RXXPDG-binding motifCell 147, 1324–1339, December 9, 2011 ª2011 Elsevier Inc. 1335
Figure 7. Radiation Chimeric Mice, which Lack Tankyrase, Phenocopy Features of Cherubism
(A) 106 Tnks2/ lineage-depleted bone marrow cells (C57Bl/6, CD45.2) were infected with a lentivirus harboring a Tnks-specific shRNA and then injected
together with 105 CD45.1 WT bone marrow cells into lethally irradiated, syngeneic (CD45.1) recipients (TNKS/2 chimera). WT control chimeric mice were
generated from CD45.2-derived bone marrow cells infected with a lentivirus expressing a scrambled shRNA hairpin (WT chimera).
(B) Fifteen weeks after transplantation, engraftment was measured by the percentage of CD45.2-positive leukocytes in the peripheral blood.
(C) Percentage of donor monocytes (CD45.2+CD11b+) in chimeric mice is shown. WT, n = 4; TNKS/2, n = 5; *p < 0.16.
1336 Cell 147, 1324–1339, December 9, 2011 ª2011 Elsevier Inc.
that is similar to the 3BP2 Tankyrase-binding peptide sequence
mutated in cherubism. In the accompanying manuscript (Guet-
tler et al., 2011), we identify sequence rules for tight binding of
targeting peptides by Tankyrase, which may facilitate the identi-
fication of previously unknown Tankyrase substrates.
Tankyrase inhibition has been proposed as a strategy to treat
Wnt-dependent tumors (Huang et al., 2009). However, the estab-
lished role for SRC in controlling osteoclast and macrophage
function (Boyce et al., 1992), in addition to its role in potentiating
tumorigenesis, suggests that sustained pharmacologic inhibition
of Tankyrase proteins might lead to the untoward effects of oste-
oporosis, myelomonocytic-mediated inflammation, or tumor
promotion. Our studies also raise the possibility that high expres-
sion of 3BP2 or loss of function of Tankyrase may contribute to
highly active SRC observed in some human cancers (Du et al.,
2009; Hynes, 2000; Irby and Yeatman, 2000; Talamonti et al.,
1993; Wiener et al., 2003).
We investigated the manner in which 3BP2 ribosylation is
coupled to ubiquitylation. Several distinct PAR-binding motifs
have recently been described, including the PAR-bindingmacro-
domain (Karras et al., 2005), a basic and hydrophobic rich motif
capable of PAR recognition present in p53, histones, and XRCC1
(Gagne´ et al., 2003; Pleschke et al., 2000), and a poly(ADP-
ribose)-binding zinc finger (PBZ) motif present in the proteins
Aprataxin PNK-like factor (APLF) and Checkpoint Protein with
FHA and RING domains (CHFR) (Ahel et al., 2008). Recently,
RNF146 has been shown to mediate the ubiquitylation of Axin2
in a ADP-ribose-dependent fashion (Zhang et al., 2011). We
show here that RNF146 binds to 3BP2 but not to cherubism
mutants and that binding is dependent on Tankyrase activity.
We show that depletion of RNF146 results in the accumulation
of 3BP2 and provokes accelerated osteoclastogenesis in
a manner observed in cherubism osteoclasts or in osteoclasts
lacking Tankyrase proteins. These data identify the E3 ligase
RNF146 as a 3BP2-dependent regulator of osteoclast activity.
It appears increasingly likely that RNF146 generally recognizes
ribosylated Tankyrase substrates.
We have identified ADP-ribosylation as a regulatory switch
that controls 3BP2 protein levels as a mechanism to modulate
SRC kinase activity and downstream signaling molecules in
osteoclasts. The necessity to maintain strict control of the
3BP2/SRC signaling module is underscored in homozygous
cherubism mutations in mice, where uncoupling of 3BP2 from
Tankyrase-mediated negative regulation results in lethality as
a result of systemic myelomonocytic cell infiltration into skin
and visceral organs. We have demonstrated that loss of this
regulatory pathway is the basis of the molecular mechanism
underlying cherubism pathogenesis. Cherubism thus represents
an example of a human developmental disease resulting from
a defect in ADP-ribosylation.(D) mCT reconstruction of the trabecular bone of WT or TNKS/2 chimeric mice 15
volume fraction (BV/TV) are shown (right). WT, n = 4; TNKS/2, n = 5; *p < 0.05.
(E) TRAP staining of tibias of WT and TNKS/2 chimeric mice.
(F and G) Histomorphometric analysis of (F) osteoclast surface to bone surface (O
WT and TNKS/2 chimeric mice 15 weeks after transplantation of donor cells. WT
(H) BMMs harvested from WT or TNKS/2 chimeric mice were grown under osteo
Error bars represent SEM. See also Figure S5.EXPERIMENTAL PROCEDURES
Mice
Sh3bp2KI/KI mice were a kind gift from Dr. Bjorn Olsen (Harvard School of
Medicine, Boston, MA, USA). Derivation of Sh3bp2/ mice has been
previously described (Chen et al., 2007). Tnks2/ mice were a kind gift from
Dr Richard Hodes (National Institutes of Health, Bethesda, MD, USA).
Chimeric Mice
Bone marrow cells fromWT or Tnks2/mice (CD45.2) were lineage depleted.
106 lineage-depleted WT or Tnks2/ bone marrow cells were infected with
pLKOTRC 020 lentivirus (TRC consortium, Broad Institute, Cambridge, MA,
USA) and then injected together with 105 CD45.1 recipient bone marrow cells
into the tail veins of 8-week-old irradiated (9Gy) B6.SJL recipient mice. Percent
chimerism was evaluated by flow cytometry for the percent CD45.2+ lympho-
cytes in the peripheral blood. For details, see the Extended Experimental
Procedures.
Microcomputed Tomography
mCT (SkyScan) was performed on tibias of chimeric mice 15 weeks after injec-
tion. For details, see the Extended Experimental Procedures.
Bone Marrow Cultures
Nucleated bone marrow cells were purified from mice femora and tibia. Oste-
oclast differentiation was induced by culturing nonadherent cells in the
presence of RANKL and CSF-1. Tartrate-resistant acid phosphatase (TRAP)
staining was performed using the Sigma reagent (386A) according tomanufac-
turer protocol. For experiments with bone marrow-derived macrophages,
nonadherent cells were cultured for 3 days in the presence of CSF-1. For
details, see the Extended Experimental Procedures.
TNF-a ELISA
TNF-a in cultured medium was measured using a TNF-a ELISA kit (eBio-
science) according to the manufacturer protocol.
Retroviral Transduction
BMMs were infected with PLKO.1 for 48 hr in the presence of 8 mg/ml poly-
brene (Sigma). Infected cells were selected in puromycin (1.6 mg/ml) for
3 days and then replated for osteoclast differentiation assay. For details, see
the Extended Experimental Procedures.
GST-Fusion Peptide Construction and Binding Assay
GST-fusion peptides encompassing either WT or cherubism mutant residues
413–418 of 3BP2 were purified and eluted from glutathione Sepharose beads
using standard procedures. HEK293T cells expressing Flag-TNKS2 were
lysed, and recombinant GST-3BP2 WT or cherubism peptide fusion proteins
were added to the lysates. Tankyrase binding to the GST-3BP2 peptides
was then determined by western blot. For details, see the Extended Experi-
mental Procedures.
Immunoprecipitation and Western Blotting
Transfected cells were lysed and precleared with protein A/G Sepharose, then
the lysates were incubated with the indicated antibody. For reprecipitation
experiments, immune complexes were dissociated in heated 1% SDS buffer
cooled and then incubated in 20 mM iodoacetamide prior to dilution with
1 ml of lysis buffer and addition of the secondary antibody for reprecipitation.
See the Extended Experimental Procedures.weeks after injection (left). mCT-derived measurements of the trabecular bone
cS/BS) and (G) osteoclast number to bone perimeter (N.Oc/BS) in the tibias of
, n = 3; TNKS/2, n = 5; *p < 0.01. Error bars represent SEM.
clastogenic conditions and TRAP stained. Scale bars: 50 mm.
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In Vitro PARP Assay
TNKS2, 3BP2 WT, or cherubism mutants were transiently expressed in
HEK293T cells for 48 hr, and then cells were lysed. 3BP2 immune complexes
were washed in 100 ml of PARP reaction buffer (50 mM Tris.HCl, pH 8.0, 4 mM
MgCl2, 0.2 mM dithiothreitol) and incubated in 100 ml of PARP reaction buffer
containing 25 mCi of [32P]NAD+ (1000 Ci/mmol; GE Healthcare) for 30 min at
25C. Following completion of the PARP reaction, beads were washed and
proteins resuspended in sample buffer, fractionated by SDS-PAGE, and the
gels dried prior to detection by autoradiography.
Statistical Analysis
Data are presented as means ± standard error of the mean (SEM). Statistic
significance was determined by Student’s t test. p value < 0.05 was consid-
ered statistically significant.
Further detailed descriptions of the RAC-GTP pull-down assay, in vitro
kinase assay, reagents and antibodies, and real-time PCR are in the Extended
Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
five figures and can be found with this article online at doi:10.1016/j.cell.
2011.10.045.
ACKNOWLEDGMENTS
This work was supported by a grant from the Terry Fox Research Institute
(TFPP Grant #20003), by the Canadian Cancer Society Research Institute,
and by the Ontario Ministry of Health and Long Term Care. The views ex-
pressed do not necessarily reflect those of the OMOHLTC. R.R. is supported
by the AmgenChair for Cancer Research from the PMHF at the Ontario Cancer
Institute, Princess Margaret Hospital. N.L. was supported by the Arthritis
Centre for Excellence Fellowship, University of Toronto. Y.U. was supported
by the Charles H. Hood Foundation, Inc., Boston, MA and research grant
R01DE020835 from the National Institutes of Health. We thank Gerald Gish
for providing the peptides and Sebastian Geuttler for assistance with the fluo-
rescence polarization experiments. We thank Ben Neel and Norman Iscove for
discussion regarding the chimera experiments. We thank Mauricio Medrano
for graphic design. We thank Frank Sicheri, Sebastian Geuttler, Ernst Reichen-
berger, Gregg Morin, Vuk Stambolic, and Ben Neel for critical reading of the
manuscript.
Received: March 11, 2010
Revised: April 4, 2011
Accepted: October 18, 2011
Published: December 8, 2011
REFERENCES
Ahel, I., Ahel, D., Matsusaka, T., Clark, A.J., Pines, J., Boulton, S.J., and West,
S.C. (2008). Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/check-
point proteins. Nature 451, 81–85.
Boyce, B.F., Yoneda, T., Lowe, C., Soriano, P., and Mundy, G.R. (1992).
Requirement of pp60c-src expression for osteoclasts to form ruffled borders
and resorb bone in mice. J. Clin. Invest. 90, 1622–1627.
Chang, P., Coughlin, M., and Mitchison, T.J. (2005). Tankyrase-1 polymeriza-
tion of poly(ADP-ribose) is required for spindle structure and function. Nat. Cell
Biol. 7, 1133–1139.
Chang, W., Dynek, J.N., and Smith, S. (2003). TRF1 is degraded by ubiquitin-
mediated proteolysis after release from telomeres. Genes Dev. 17, 1328–1333.
Chen, B., Dodge, M.E., Tang, W., Lu, J., Ma, Z., Fan, C.W., Wei, S., Hao, W.,
Kilgore, J., Williams, N.S., et al. (2009). Small molecule-mediated disruption of
Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol.
5, 100–107.1338 Cell 147, 1324–1339, December 9, 2011 ª2011 Elsevier Inc.Chen, G., Dimitriou, I.D., La Rose, J., Ilangumaran, S., Yeh, W.C., Doody, G.,
Turner, M., Gommerman, J., and Rottapel, R. (2007). The 3BP2 adapter protein
is required for optimal B-cell activation and thymus-independent type 2
humoral response. Mol. Cell. Biol. 27, 3109–3122.
Chiang, Y.J., Hsiao, S.J., Yver, D., Cushman, S.W., Tessarollo, L., Smith, S.,
and Hodes, R.J. (2008). Tankyrase 1 and tankyrase 2 are essential but redun-
dant for mouse embryonic development. PLoS ONE 3, e2639.
Chiang, Y.J., Nguyen, M.L., Gurunathan, S., Kaminker, P., Tessarollo, L., Cam-
pisi, J., and Hodes, R.J. (2006). Generation and characterization of telomere
length maintenance in tankyrase 2-deficient mice. Mol. Cell. Biol. 26, 2037–
2043.
Cicchetti, P., Mayer, B.J., Thiel, G., and Baltimore, D. (1992). Identification of
a protein that binds to the SH3 region of Abl and is similar to Bcr and
GAP-rho. Science 257, 803–806.
de la Fuente, M.A., Kumar, L., Lu, B., and Geha, R.S. (2006). 3BP2 deficiency
impairs the response of B cells, but not T cells, to antigen receptor ligation.
Mol. Cell. Biol. 26, 5214–5225.
Deckert, M. (2006). [The adaptor protein 3BP2 in leukocyte signaling]. Med.
Sci. (Paris) 22, 1081–1086.
Deckert, M., and Rottapel, R. (2006). The adapter 3BP2: how it plugs into
leukocyte signaling. Adv. Exp. Med. Biol. 584, 107–114.
Du, J., Bernasconi, P., Clauser, K.R., Mani, D.R., Finn, S.P., Beroukhim, R.,
Burns, M., Julian, B., Peng, X.P., Hieronymus, H., et al. (2009). Bead-based
profiling of tyrosine kinase phosphorylation identifies SRC as a potential target
for glioblastoma therapy. Nat. Biotechnol. 27, 77–83.
Gagne´, J.P., Hunter, J.M., Labrecque, B., Chabot, B., and Poirier, G.G. (2003).
A proteomic approach to the identification of heterogeneous nuclear ribonu-
cleoproteins as a new family of poly(ADP-ribose)-binding proteins. Biochem.
J. 371, 331–340.
Guettler, S., LaRose, J., Petsalaki, E., Gish, G., Scotter, A., Pawson, T., Rotta-
pel, R., and Sicheri, F. (2011). Structural basis and sequence rules for substrate
recognition by Tankyrase explain the basis for cherubism disease. Cell 147,
this issue, 1340–1354.
Hsiao, S.J., Poitras, M.F., Cook, B.D., Liu, Y., and Smith, S. (2006). Tankyrase
2 poly(ADP-ribose) polymerase domain-deleted mice exhibit growth defects
but have normal telomere length and capping. Mol. Cell. Biol. 26, 2044–2054.
Huang, S.M., Mishina, Y.M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G.A.,
Charlat, O., Wiellette, E., Zhang, Y., Wiessner, S., et al. (2009). Tankyrase inhi-
bition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614–620.
Hynes, N.E. (2000). Tyrosine kinase signalling in breast cancer. Breast Cancer
Res. 2, 154–157.
Irby, R.B., and Yeatman, T.J. (2000). Role of Src expression and activation in
human cancer. Oncogene 19, 5636–5642.
Jones, W.A., Gerrie, J., and Pritchard, J. (1950). Cherubism—familial fibrous
dysplasia of the jaws. J. Bone Joint Surg. Br. 32-B, 334–347.
Karras, G.I., Kustatscher, G., Buhecha, H.R., Allen, M.D., Pugieux, C., Sait, F.,
Bycroft, M., and Ladurner, A.G. (2005). The macro domain is an ADP-ribose
binding module. EMBO J. 24, 1911–1920.
Levaot, N., Simoncic, P.D., Dimitriou, I.D., Scotter, A., La Rose, J., Ng, A.H.,
Willett, T.L., Wang, C.J., Janmohamed, S., Grynpas, M., et al. (2011). 3BP2-
deficient mice are osteoporotic with impaired osteoblast and osteoclast func-
tions. J. Clin. Invest. 121, 3244–3257.
Lietman, S.A., Kalinchinko, N., Deng, X., Kohanski, R., and Levine, M.A. (2006).
Identification of a novel mutation of SH3BP2 in cherubism and demonstration
that SH3BP2 mutations lead to increased NFAT activation. Hum. Mutat. 27,
717–718.
Pleschke, J.M., Kleczkowska, H.E., Strohm, M., and Althaus, F.R. (2000).
Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint
proteins. J. Biol. Chem. 275, 40974–40980.
Sada, K., Miah, S.M., Maeno, K., Kyo, S., Qu, X., and Yamamura, H. (2002).
Regulation of FcepsilonRI-mediated degranulation by an adaptor protein
3BP2 in rat basophilic leukemia RBL-2H3 cells. Blood 100, 2138–2144.
Smith, S., Giriat, I., Schmitt, A., and de Lange, T. (1998). Tankyrase, a
poly(ADP-ribose) polymerase at human telomeres. Science 282, 1484–1487.
Talamonti, M.S., Roh, M.S., Curley, S.A., and Gallick, G.E. (1993). Increase in
activity and level of pp60c-src in progressive stages of human colorectal
cancer. J. Clin. Invest. 91, 53–60.
Tiziani, V., Reichenberger, E., Buzzo, C.L., Niazi, S., Fukai, N., Stiller, M.,
Peters, H., Salzano, F.M., Raposo do Amaral, C.M., and Olsen, B.R. (1999).
The gene for cherubism maps to chromosome 4p16. Am. J. Hum. Genet.
65, 158–166.
Ueki, Y., Tiziani, V., Santanna, C., Fukai, N., Maulik, C., Garfinkle, J., Ninomiya,
C., doAmaral, C., Peters, H., Habal, M., et al. (2001). Mutations in the gene en-
coding c-Abl-binding protein SH3BP2 cause cherubism. Nat. Genet. 28,
125–126.
Ueki, Y., Lin, C.Y., Senoo, M., Ebihara, T., Agata, N., Onji, M., Saheki, Y.,
Kawai, T., Mukherjee, P.M., Reichenberger, E., and Olsen, B.R. (2007).Increased myeloid cell responses to M-CSF and RANKL cause bone loss
and inflammation in SH3BP2 ‘‘cherubism’’ mice. Cell 128, 71–83.
Wiener, J.R., Windham, T.C., Estrella, V.C., Parikh, N.U., Thall, P.F., Deavers,
M.T., Bast, R.C., Mills, G.B., and Gallick, G.E. (2003). Activated SRC protein
tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gyne-
col. Oncol. 88, 73–79.
Yeh, T.Y., Beiswenger, K.K., Li, P., Bolin, K.E., Lee, R.M., Tsao, T.S., Murphy,
A.N., Hevener, A.L., and Chi, N.W. (2009). Hypermetabolism, hyperphagia,
and reduced adiposity in tankyrase-deficient mice. Diabetes 58, 2476–2485.
Zhang, Y., Liu, S., Mickanin, C., Feng, Y., Charlat, O., Michaud, G.A., Schirle,
M., Shi, X., Hild, M., Bauer, A., et al. (2011). RNF146 is a poly(ADP-ribose)-
directed E3 ligase that regulates axin degradation and Wnt signalling. Nat.
Cell Biol. 13, 623–629.Cell 147, 1324–1339, December 9, 2011 ª2011 Elsevier Inc. 1339
